Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
Recruiting · NCT05901285 · Registry updated 2026-08-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors | Advanced Solid Tumor; Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab | Recruiting | Phase 1 | 2026-08-24 | NCT05901285 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Vaxiion Therapeutics | 1 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Atlantic Health System | Morristown | United States | 17 |
| Cleveland Clinic | Cleveland | United States | 558 |
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Dartmouth Cancer Center | Lebanon | United States | 5 |
| George Washington University | Washington D.C. | United States | 14 |
| Melanoma & Skin Cancer Institute | Denver | United States | 1 |
| Sarah Cannon Research Institute at HealthOne | Denver | United States | 34 |
| University of Arizona Cancer Center | Tucson | United States | 21 |